---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-072832"
form_type: "8-K"
ticker: "BRKR"
cik: "0001109354"
company_name: "BRUKER CORP"
filed_at: "2023-12-26T23:59:59+00:00"
generated_at: "2026-06-07T07:12:52.962978+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bruker agrees to acquire ELITechGroup for €870M enterprise value; Q2 2024 close expected

## Summary
- Enterprise Value of €870 million; cash purchase price with cash on hand.
- Target projected 2023 revenue of €150M, majority recurring; accretive to non-GAAP EPS in FY2024.
- Put option exercisable after French and Dutch works council consultations; 12-month exclusivity.
- Bruker provided equity commitment letter and secured W&I insurance for seller reps.
- Acquisition is subject to regulatory approvals and carve-out of clinical chemistry business.

## SEC filing metadata
- accession: 0000950170-23-072832
- form_type: 8-K
- ticker: BRKR
- cik: 0001109354
- company_name: BRUKER CORP
- filed_at: 2023-12-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1109354/000095017023072832/0000950170-23-072832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1109354/000095017023072832/brkr-20231226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-072832
- JSON: https://secwatch.observer/filing/0000950170-23-072832.json
- Plain text: https://secwatch.observer/filing/0000950170-23-072832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.